Article Text

Download PDFPDF
The authors’ reply:
  1. K Gjesdal,
  2. J Feyzi,
  3. S B Olsson
  1. Arrhythmia Centre, Ullevål University Hospital, Oslo, Norway
  1. Professor K Gjesdal, Arrhythmia Centre, Ullevål University Hospital, Kirkeveien 166, Oslo, 0407 Norway; knut.gjesdal{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Testa and coworkers raise a number of questions related to our article1 on suspected increased mortality in patients with atrial fibrillation treated with digitalis. The only method for settling the question would be to perform a randomised controlled clinical trial on digitalis versus placebo in atrial fibrillation, with mortality as the primary outcome. For obvious reasons such a trial will probably not be done. The sample size would need to be large, long-term follow-up would be required, and …

View Full Text

Linked Articles